← Browse by Condition
Medical Condition

age related macular degeneration

Total Trials
5
Recruiting Now
5
Trial Phases
Phase 1, Phase 3

ClinicalMetric tracks all active clinical trials for age related macular degeneration sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — age related macular degeneration Clinical Trials

How many clinical trials are currently recruiting for age related macular degeneration?
ClinicalMetric currently tracks 5 actively recruiting clinical trials for age related macular degeneration, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 5. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for age related macular degeneration?
age related macular degeneration research spans Phase 1 (1 trial), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a age related macular degeneration clinical trial?
Eligibility criteria for age related macular degeneration trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Phase 3
1
Top Sponsors
Benobio Co., Ltd. 1 trial
University of Minnesota 1 trial
Duke University 1 trial
Yeungnam University College of Medicine 1 trial
Medical University of Vienna 1 trial

Recruiting Clinical Trials

NCT05803785 Phase 1
Recruiting

Safety of BBC1501 Intravitreal Injection in Patients With Neovascular Age-Related Macular Degeneration (nAMD)

Enrollment
18 pts
Location
Australia
Sponsor
Benobio Co., Ltd.
View Trial →
NCT03848663
Recruiting

Visual Remapping to Aid Reading With Field Loss

Enrollment
108 pts
Location
United States
Sponsor
University of Minnesota
View Trial →
NCT06619405
Recruiting

AMD and Validation Rod-Meditated Dark Adaptation With Everyday Task Performance

Enrollment
100 pts
Location
United States
Sponsor
Duke University
View Trial →
NCT07461441 Phase 3
Recruiting

Efficacy and Durability of a Personalized Treat-and-extend Regimen of Faricimab for Treatment-naive Polypoidal Choroidal Vasculopathy

Enrollment
50 pts
Location
South Korea
Sponsor
Yeungnam University College of...
View Trial →
NCT06351670
Recruiting

Personalised Monitoring of Early and Intermediate Age-related Macular Degeneration With Artificial Intelligence and Identification of Disease Progression

Enrollment
500 pts
Location
Austria, France, Slo...
Sponsor
Medical University of Vienna
View Trial →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology